首页> 外文期刊>The Journal of Allergy and Clinical Immunology >Allergic Rhinitis and its impact on Asthma (ARIA): Achievements in 10 years and future needs
【24h】

Allergic Rhinitis and its impact on Asthma (ARIA): Achievements in 10 years and future needs

机译:过敏性鼻炎及其对哮喘的影响(ARIA):10年的成就和未来需求

获取原文
获取原文并翻译 | 示例
           

摘要

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassifled AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.
机译:过敏性鼻炎(AR)和哮喘代表了所有年龄段的全球健康问题。哮喘和鼻炎经常并存于同一受试者中。过敏性鼻炎及其对哮喘的影响(ARIA)是在1999年世界卫生组织的一次研讨会上发起的(于2001年出版)。 ARIA将AR重新分类为轻度/中度-重度和间歇/持续性。此分类紧密反映患者的需求,并强调鼻炎和哮喘之间的密切关系。病人,临床医生和其他卫生保健专业人员面对各种治疗AR的治疗选择。这导致临床实践中的巨大差异,并且在世界范围内,患者,临床医生和其他医疗保健专业人员面临着各种治疗方案相对优缺点的不确定性。在其2010年修订版中,ARIA在推荐,评估,开发和评估(GRADE)分级系统的基础上,制定了AR和哮喘合并症管理的临床实践指南。 ARIA已在世界50多个国家/地区传播和实施。在《 ARIA世界卫生组织研讨会报告》发布十年后,重要的是总结其成就并确定仍未得到满足的临床,研究和实施需求,以加强2011年欧盟对儿童过敏和哮喘的优先考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号